Compounds having activity as mTOR inhibitors are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
揭示了具有作为
mTOR 抑制剂活性的化合物。这些化合物具有以下结构(I),包括立体异构体、药用可接受的盐和前药,其中 R1、R2、R3、R4 和 A 如本文所定义。还公开了与制备和使用这些化合物相关的方法,以及包含这些化合物的药物组合物。